GABELLI HEALTHCARE & WELL (GRX) Stock Price, Forecast & Analysis
USA - NYSE:GRX - US36246K1034
9.1928 USD
-0.06 (-0.62%)
Taking everything into account, GRX scores 2 out of 10 in our fundamental rating. GRX was compared to 0 industry peers in the Unkown industry. GRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GRX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GRX had negative earnings in the past year.
In the past year GRX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: GRX reported negative net income in multiple years.
GRX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.36% | ||
| ROE | -0.43% | ||
| ROIC | N/A |
ROA(3y)-6.34%
ROA(5y)0.14%
ROE(3y)-7.71%
ROE(5y)0.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, GRX has about the same amount of shares outstanding.
Compared to 5 years ago, GRX has less shares outstanding
GRX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.91 indicates that GRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Debt to FCF ratio of GRX is 1.00, which is an excellent value as it means it would take GRX, only 1.00 years of fcf income to pay off all of its debts.
GRX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
Although GRX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1 | ||
| Altman-Z | 2.91 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 4.51 indicates that GRX has no problem at all paying its short term obligations.
A Quick Ratio of 4.51 indicates that GRX has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.51 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
GRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.11%, which is quite impressive.
Looking at the last year, GRX shows a decrease in Revenue. The Revenue has decreased by -0.82% in the last year.
GRX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.67% yearly.
EPS 1Y (TTM)86.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y2.57%
Revenue growth 5Y-0.67%
Sales Q2Q%-2.96%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GRX. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.29 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
GRX has a Yearly Dividend Yield of 6.96%, which is a nice return.
Compared to an average S&P500 Dividend Yield of 2.37, GRX pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.96% |
5.2 History
GRX has been paying a dividend for at least 10 years, so it has a reliable track record.
GRX has decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years2
5.3 Sustainability
GRX has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-1357.75%
EPS Next 2YN/A
EPS Next 3YN/A
NYSE:GRX (11/7/2025, 8:04:00 PM)
9.1928
-0.06 (-0.62%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners37.35%
Inst Owner Change-0.76%
Ins Owners1.83%
Ins Owner Change0%
Market Cap142.03M
Revenue(TTM)3.76M
Net Income(TTM)-710.00K
Analysts0
Price TargetN/A
Short Float %0.05%
Short Ratio0.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.96% |
Yearly Dividend0.59
Dividend Growth(5Y)N/A
DP-1357.75%
Div Incr Years0
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 37.77 | ||
| P/FCF | 4.29 | ||
| P/OCF | 4.29 | ||
| P/B | 0.87 | ||
| P/tB | 0.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)2.14
FCFY23.28%
OCF(TTM)2.14
OCFY23.28%
SpS0.24
BVpS10.55
TBVpS10.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.36% | ||
| ROE | -0.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 879.52% |
ROA(3y)-6.34%
ROA(5y)0.14%
ROE(3y)-7.71%
ROE(5y)0.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.51 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z | 2.91 |
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.82%
Revenue growth 3Y2.57%
Revenue growth 5Y-0.67%
Sales Q2Q%-2.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.01%
OCF growth 3YN/A
OCF growth 5YN/A
GABELLI HEALTHCARE & WELL / GRX FAQ
Can you describe the business of GABELLI HEALTHCARE & WELL?
Gabelli Healthcare & WellnessRx Trust is a US-based company operating in industry. The company is headquartered in Rye, New York. The company went IPO on 2007-06-19. The Gabelli Healthcare and WellnessRx Trust (the Fund) is a non-diversified closed-end management investment company. The Fund’s investment objective is long term growth of capital. Under normal market conditions, the Fund will invest at least 80% of its net assets (plus borrowings made for investment purposes) in equity securities (such as common stock and preferred stock) and income producing securities (such as fixed income debt securities and securities convertible into common stock) of domestic and foreign companies in the healthcare and wellness industries. The company invests in various sector, such as beverages, biotechnology, electronics, equipment and supplies, food, health care providers and service, household and personal products, and pharmaceuticals. The Fund’s investment adviser is Gabelli Funds, LLC.
What is the stock price of GABELLI HEALTHCARE & WELL today?
The current stock price of GRX is 9.1928 USD. The price decreased by -0.62% in the last trading session.
What is the ChartMill rating of GABELLI HEALTHCARE & WELL stock?
GRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.